GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spexis AG (XSWX:SPEX) » Definitions » Cash Receipts from Operating Activities

Spexis AG (XSWX:SPEX) Cash Receipts from Operating Activities


View and export this data going back to 2018. Start your Free Trial

What is Spexis AG Cash Receipts from Operating Activities?

Cash Receipts from Operating Activities only applicable to companies reporting Cash Flow from Operations in direct method.


Spexis AG (XSWX:SPEX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spexis AG (XSWX:SPEX) » Definitions » Cash Receipts from Operating Activities
Traded in Other Exchanges
Address
Hegenheimermattweg 125, Allschwil, CHE, CH-4123
Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.